4119 — SCI Pharmtech Cashflow Statement
0.000.00%
Last trade - 00:00
- TWD10.58bn
- TWD10.59bn
- TWD1.20bn
- 35
- 20
- 51
- 23
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 711 | 455 | 65.5 | 388 | 364 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -10.5 | 577 | 5.36 | -73.2 | 37.5 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -45.8 | -194 | 146 | -109 | -331 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 792 | 972 | 280 | 297 | 216 |
Capital Expenditures | -204 | -218 | -775 | -1,168 | -1,029 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -59 | -211 | 235 | 158 | 163 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -263 | -429 | -540 | -1,009 | -866 |
Financing Cash Flow Items | — | — | — | 1 | 0 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -336 | -463 | -41.5 | 547 | 1,426 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 192 | 79.5 | -301 | -165 | 775 |